ArticleInfection and drug resistance2025
Diagnostic Performance of Nucleotide MALDI-TOF-MS for the Rapid Diagnosis of Pulmonary Tuberculosis and the Detection of Drug Resistance.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the diagnostic performance of nucleotide MALDI-TOF-MS in the rapid diagnosis of pulmonary tuberculosis and the detection of drug resistance. Methods: A retrospective study was conducted on suspected pulmonary tuberculosis patients (total of 110) admitted to Affiliated Hospital of Hangzhou Normal University between November 2020 to April 2024. The age of all patients range of the patients was 19 to 90 years, and the mean age was 55.1±20.9 years. Of the enrolled participants, 59 (53.6%) were males and 51 (46.4%) were females. The study involved calculating and comparing the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of nucleotide MALDI-TOF-MS, MGIT960 culture, and Xpert MTB/RIF. Results: According to the clinical diagnosis reference standard, the sensitivity, specificity, PPV, and NPV of nucleotide MALDI-TOF-MS for detecting Mycobacterium tuberculosis (MTB) were 84.2% (95% CI: 74.4-94.0%), 92.5% (85.1-99.8%), 92.3% (84.8-99.8%), and 84.5% (74.9-94.4%). The MGIT960 culture method served as the reference standard, and the nucleotide MALDI-TOF-MS demonstrated a sensitivity of 100.0% (95% CI: 88.3-100%), specificity of 71.6% (61.6-81.6%), PPV of 55.8% (41.8-69.7%), and NPV of 100.0% (93.8-100.0%) in identifying MTB. Regarding drug resistance, the nucleic acid MALDI-TOF-MS technique shows a high level of agreement with conventional culture methods in identifying resistance to isoniazid, rifampicin, streptomycin and ethambutol. Conclusion: Nucleotide MALDI-TOF-MS demonstrates good diagnostic efficacy in the rapid diagnosis of pulmonary tuberculosis and the assessment of drug resistance, positioning it as a promising technique for the diagnosis of Mycobacterium tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.